secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2022-06-08T23:59:59+00:00
Accession:  0000950142-22-001844
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals appoints Seth Van Voorhees as CFO and Treasurer, effective June 13, 2022
--------------------------------------------------------------------------------

- Van Voorhees most recently CFO of PDS Biotechnology; prior CFO at Research Frontiers and American Pacific.
- Employment agreement: $400k annual base salary, $200k target bonus, and option grant for 325,000 shares with two-year vesting.
- Severance: nine months' salary plus prorated bonus and accelerated vesting on termination without cause or change of control.
- Company focusing resources on psychiatry franchise, particularly NRX-101 for bipolar depression with suicidality.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000095014222001844/0000950142-22-001844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000095014222001844/eh220259882_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-22-001844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer